

Efficacy and safety of Teneiglipitin in patients of Type 2 Diabetes Mellitus with Chronic Kidney Disease: ATEND-CKD Study

IJIRMS, Vol 04 Issue 01 Jan 2019

- Prior studies have estimated prevalence of CKD with type 2 diabetes mellitus at approx.35 to 42%.
- Phase 4, multi-centric, open labelled, non-comparative study on 405 patients diagnosed with CKD due to uncontrolled type 2 diabetes mellitus.
- Teneiglipitin reported significant mean reduction in FPG and PPBG by 40.4 and 57.5 mg/dl respectively. At 12 weeks 0.9% reduction in HbA1c was noted.
- Reduction in the renal parameters like sr.creatinine and blood urea nitrogen (BUN) by 4% and 9% respectively was recorded.

The study reported significant improvement in the glycaemic control, serum creatinine and BUN with Teneiglipitin indicating significant impact in the management of type 2 diabetic patients with renal impairment.